Adenocarcinome gastrique a Brazzaville : recherche de la surexpression de l’oncoproteine HER2 par immunohistochimie:

Introduction : la surexpression et/ou l’amplification du gene HER2 est observee dans differentes tumeurs incluant les tumeurs gastriques. Elle est decrite dans 10 a 30% des adenocarcinomes gastriques. Un statut Her2 positif est un facteur de mauvais pronostic et un facteur predictif de la reponse a une therapie ciblee, le trastuzumab (herceptinR). Le but de notre etude est de rechercher la surexpression de l’oncoproteine Her2 dans les adenocarcinomes gastriques avances. Materiels et Methodes : la recherche de la surexpression de Her2 a ete realisee sur les prelevements de tissus gastriques carcinomateux (biopsies et pieces operatoires) inclus en paraffine par immunohistochimie. Les echantillons ont ete collectes retrospectivement entre Janvier 2008 et decembre 2018.Resultats : durant cette periode, 52 prelevements ont ete analyses. 9,6% des tumeurs surexprimaient Her2. Conclusion : vu le mauvais pronostic de l’adenocarcinome gastrique, la recherche de la surexpression de l'oncoproteine Her2 est devenue indispensable pour selectionner les patients susceptibles de beneficier d’une therapie ciblee anti-HER2. ABSTRACTIntroduction: The over expression of oncoprotein'Her2 has been detected in several cancers and has been particularly studied in breast cancer. It is described in 10 to 30% of gastric adenocarcinomas. A positive Her2 status is a factor of poor prognosis and a predictor of the response to herceptin (trastuzumab). The aim of our study is to investigate the over expression of Her2 oncoprotein in advanced gastric adenocarcinomas while comparing our results with those of the literature. Materials and Methods: The search for over expression of the Her2 oncoprotein is determined on samples of tumor gastric tissues (biopsies and surgical pieces) included in paraffin by the immunohistochemistrytechnique, over a period of 11 years (January 2008- December 2018). Results: During this period, 52 cases of Tumor gastric tissue samples (biopsies and operating pieces) were examined, the rate of cases over expressing the Her2 oncoprotein in our study is 9.6%, this over expression remains within the limit of most series of literature including a large study called ToGA.Conclusion: Given the poor prognosis for gastric adenocarcinoma, the search for over expression of the Her2 oncoprotein has become essential in order to select the patients likely to benefit from treatment with Herceptin.